2018 Volume 1 Issue 3 Pages 177-182
A 55-year-old man, medicated with a dipeptidyl peptidase-4 inhibitor for type 2 diabetes, presented with itching rash on his whole body 7 years after a diagnosis of systemic lupus erythematosus. Hypereosinophilia and high serum levels of IgE and TARC were present. Histopathologically, the rash was chronic dermatitis. We diagnosed the patient as atopic dermatitis. The rash was improved by treatment with topical steroids and oral antihistaminergic medicine. Simultaneously, eosinophilia and increased TARC were also improved. In addition, anti-BP180 antibody was positive at the onset of rash although there were no blisters and a direct immunofluorescence test was negative. We speculated that Th2 activation might have been induced by the disease state of systemic lupus erythematosus and a dipeptidyl peptidase-4 inhibitor, which led to atopic dermatitis, as well as the appearance of the anti-BP180 antibody.
